Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582749 · ClinicalTrials.gov registry record · Phase 2
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
A Phase 2 study, sponsored by Ajjai Alva, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02582749: Clinical Trial Phase 2 study, sponsored by Ajjai Alva, MD.
NCT02582749 is a Phase 2 study that was terminated before completion, run by Ajjai Alva, MD. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02582749, a Phase 2 study, was terminated before completion, sponsored by Ajjai Alva, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
Primary Outcome
rPFS assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) to compare outcomes of subjects on experimental arm vs control arm
Interventions
- DRUG Bicalutamide
- DRUG LHRH agonist/antagonist
- RADIATION Radium-223 dichloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 2 |
Why NCT02582749 stopped before completion
NCT02582749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which Bicalutamide is the first listed.
NCT02582749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02582749 about?
NCT02582749 is a clinical study titled "Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases". Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
What is the current status of trial NCT02582749?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-04. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02582749?
The interventions under investigation include: Bicalutamide (DRUG), LHRH agonist/antagonist (DRUG), Radium-223 dichloride (RADIATION).
Who is sponsoring clinical trial NCT02582749?
This trial is sponsored by Ajjai Alva, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02582749's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia